Lupin Limited (Lupin) the Mumbai based Indian pharma major on 08th June announced its strategic collaboration with LABORATORIOS ERN S.A. (ERN), a renowned Spanish pharmaceutical company, for the launch of Luforbec® (beclometasone/formoterol) 100/6, a fixed dose combination in a pressurized metered dose inhaler(pMDI)in the Spain.
Luforbec® is widely used for the regular treatment of asthma, where the use of a combination product (inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) is appropriate. Luforbec® is also indicated in the symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
This collaboration will bring together Lupin’s global respiratory expertise and proven pMDI manufacturing excellence with ERN’s robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain.
Lupin’s President for EMEA and Emerging Markets, Thierry Volle said, “The launch of Luforbec® in Spain, following successful introductions in the UK and Germany, represents a key milestone in our partnership with ERN and reinforces our commitment to advancing global access to quality respiratory care. Together, we are building something truly exciting for patients and healthcare professionals.
“Partnering with Lupin allows us to bring a proven, high-value respiratory therapy to Spanish patients and healthcare professionals. It represents an opportunity for ERN to expand into a new therapeutic area,” said David Solanes, the CEO of LABORATORIOS ERN, S.A.
Written by: Pramit Hazra
Graphics by: Pramit Hazra
